Jazz Pharmaceuticals Issues Joint Press Release with Actio Biosciences

What Happened

• On August 10, 2026, Jazz Pharmaceuticals plc and Actio Biosciences, Inc. issued a joint press release. Jazz filed an SEC Form 8‑K (Item 7.01) to furnish that press release (attached as Exhibit 99.1). The disclosure was made pursuant to Regulation FD and the information is furnished, not filed, with the SEC.

Key Details

• Date of disclosure: August 10, 2026.
• Companies involved: Jazz Pharmaceuticals plc (JAZZ) and Actio Biosciences, Inc.
• Exhibit included: Press Release dated August 10, 2026 (Exhibit 99.1) — furnished under Item 7.01.
• Filing accession number: 0001193125-26-341270. The 8‑K also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters

• This 8‑K signals that Jazz and Actio made material information public via a joint press release; Regulation FD filing ensures the information was shared broadly. The 8‑K itself does not summarize the press release contents, so investors should read Exhibit 99.1 (the press release) for details on any corporate, clinical, commercial or financial developments and monitor further SEC filings for material impacts.